Champions Oncology Stock Current Ratio
| CSBR Stock | USD 10.53 0.27 2.63% |
Champions Oncology fundamentals help investors to digest information that contributes to Champions Oncology's financial success or failures. It also enables traders to predict the movement of Champions Stock. The fundamental analysis module provides a way to measure Champions Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Champions Oncology stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 0.73 | 0.69 |
Champions | Current Ratio |
Champions Oncology Company Current Ratio Analysis
Champions Oncology's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Champions Oncology Current Ratio | 1.11 X |
Most of Champions Oncology's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Champions Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Champions Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Champions Oncology is extremely important. It helps to project a fair market value of Champions Stock properly, considering its historical fundamentals such as Current Ratio. Since Champions Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Champions Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Champions Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
Champions Current Ratio Historical Pattern
Today, most investors in Champions Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Champions Oncology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Champions Oncology current ratio as a starting point in their analysis.
Champions Oncology Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Champions Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Champions Oncology has a Current Ratio of 1.11 times. This is 61.86% lower than that of the Life Sciences Tools & Services sector and 84.14% lower than that of the Health Care industry. The current ratio for all United States stocks is 48.61% higher than that of the company.
Champions Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Champions Oncology's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Champions Oncology could also be used in its relative valuation, which is a method of valuing Champions Oncology by comparing valuation metrics of similar companies.Champions Oncology is currently under evaluation in current ratio category among its peers.
Champions Oncology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Champions Oncology from analyzing Champions Oncology's financial statements. These drivers represent accounts that assess Champions Oncology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Champions Oncology's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 141.0M | 101.4M | 65.8M | 65.7M | 59.1M | 46.0M | |
| Enterprise Value | 145.9M | 101.8M | 64.3M | 70.5M | 63.5M | 44.4M |
Champions Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Champions Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Champions Oncology's managers, analysts, and investors.Environmental | Governance | Social |
Champions Fundamentals
| Return On Equity | -1.55 | ||||
| Return On Asset | -0.0082 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 135.26 M | ||||
| Shares Outstanding | 13.7 M | ||||
| Shares Owned By Insiders | 25.89 % | ||||
| Shares Owned By Institutions | 47.81 % | ||||
| Number Of Shares Shorted | 104.28 K | ||||
| Price To Earning | 220.00 X | ||||
| Price To Book | 192.71 X | ||||
| Price To Sales | 2.62 X | ||||
| Revenue | 50.16 M | ||||
| Gross Profit | 23.97 M | ||||
| EBITDA | (5.05 M) | ||||
| Net Income | (7.28 M) | ||||
| Cash And Equivalents | 8.06 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 7.43 M | ||||
| Debt To Equity | 1.03 % | ||||
| Current Ratio | 1.11 X | ||||
| Book Value Per Share | 0.05 X | ||||
| Cash Flow From Operations | (6.14 M) | ||||
| Short Ratio | 1.73 X | ||||
| Earnings Per Share | (0.05) X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 210 | ||||
| Beta | 0.28 | ||||
| Market Capitalization | 140.55 M | ||||
| Total Asset | 26.13 M | ||||
| Retained Earnings | (84.59 M) | ||||
| Working Capital | (7.9 M) | ||||
| Current Asset | 4.34 M | ||||
| Current Liabilities | 5.31 M | ||||
| Net Asset | 26.13 M |
About Champions Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Champions Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Champions Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Champions Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Champions Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.Moving together with Champions Stock
| 0.68 | PFE | Pfizer Inc Aggressive Push | PairCorr |
Moving against Champions Stock
| 0.62 | NIO | Nio Class A Buyout Trend | PairCorr |
| 0.57 | RIG | Transocean | PairCorr |
| 0.56 | ILMN | Illumina | PairCorr |
| 0.56 | CRSP | Crispr Therapeutics | PairCorr |
| 0.52 | DD | Dupont De Nemours | PairCorr |
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.